Eyubova U
Actuality: Heart failure has become a topical issue in world health recent years due to the high prevalence, rehospitalization, poor prognosis and mortality rate. As the principal pathophysiological mechanism of the progression of this pathology, the focus is on left-ventricular dysfunction, neurohumoral activity and ventricular remodelling. In recent years, numerous studies on the pathogenesis of the disease has revealed important advances in the treatment of the disease. One of them is the detailed study of the role of BNP in the pathogenesis of the disease and the use of therapies based on this.
Purpose: To study the effects of sacubitril/valsartan combination in patients with long-term chronic heart failure, whose left ventricular ejection fraction is below 40%.
Materials & methods: The results of 30 men and women suffering from long-term chronic heart failure with left ventricular ejection fraction below 40% were studied. Patients were over 25 years of age. Each patient was given a combination of sacubitril / valsartan 200 mg daily (100 mg in the morning and 100 mg in the evening). The patients were re-examined 6 months later with transtoracic echocardiography.
Results of study: An increase in the left ventricular ejection fraction in the majority of patients was observed post-transtoracic echocardiography after 6 months.
Summary: The study found a positive effect of adding the sacubitril / valsartan combination to the treatment of chronic heart failure in the majority of patients with the left ventricular ejection fraction
Comparte este artículo
English 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 